Medincell SA (id:10806 MEDCL)
18.10 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/28/2024 1:43:29 AM)
Exchange closed, opens in 7 hours 16 minutes
About Medincell SA
Market Capitalization 525.96M
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
| Headquarters (address) |
3 rue des FrEres LumiEre Jacou 34830 France |
| Phone | 33 4 67 02 13 67 |
| Website | https://www.medincell.com |
| Employees | 134 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MEDCL |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 5.92 - 19.00 |
| Market Capitalization | 525.96M |
| P/E trailing | -20.57 |
| P/E forward | 90.40 |
| Price/Sale | 44.03 |
| Beta | 1.20 |
| EPS | -0.880 |
| EPS France (ID:70, base:331) | 3.06 |